VolitionRx VNRX · Analysis & News
Heads-up: USD Core CPI is due in 4 h (high impact). The outlook can shift noticeably around it.
Heads-up: USD Core CPI y/y is due in 4 h (high impact). The outlook can shift noticeably around it.
Heads-up: USD CPI y/y is due in 4 h (high impact). The outlook can shift noticeably around it.
Heads-up: USD Core CPI m/m is due in 4 h (high impact). The outlook can shift noticeably around it.
Heads-up: USD CPI is due in 4 h (high impact). The outlook can shift noticeably around it.
Heads-up: USD CPI m/m is due in 4 h (high impact). The outlook can shift noticeably around it.
Heads-up: USD Core CPI n.s.a. m/m is due in 4 h (high impact). The outlook can shift noticeably around it.
VolitionRx looks bullish on fundamentals after it cut its convertible note to $0.7 million and pushed back conversion rights to January 2027, sharply reducing dilution risk. With no technical picture available, the balance sheet is the main evidence.
News situation · 2 items / 30 D
2 of 2 straight from the issuer or regulator
Outlook for VolitionRx
Direction, typical moves and upcoming dates from our own price, news and calendar data, recalculated on every visit. An assessment, not investment advice.
What drives it
- Debt reduced by over $5.0 million since June 30, 2026, materially strengthening the financing position.
- Convertible note prepaid down to $0.7 million principal, leaving a far lighter debt burden.
- Conversion rights are frozen until January 2027, removing near-term share dilution pressure.
What argues against it
- The remaining $0.7 million note still carries conversion or repayment obligations.
- If the closing share price reaches $0.275, conversion rights can be triggered earlier.
- Third quarter results are due with the earnings call on November 13 and will be the next real test.
- High-impact US inflation readings due shortly set the macro backdrop without giving the stock a direction.
What would change the picture
- Third quarter results on November 13, better or worse than expected, would shift the picture.
- A closing share price at or above $0.275 could unfreeze the conversion moratorium before January 2027.
Coming up
- US: Consumer prices · expected 2.8%, previous 2.6%
- US: Jobless claims
Economic data for VNRX
Full calendarComing up
- TodayUSDCore CPI●●●Forecast 339.796Previous 338.896in 4h
- TodayUSDCore CPI y/y●●●Forecast 2.8%Previous 2.6%in 4h
- TodayUSDCPI y/y●●●Forecast 4.2%Previous 3.7%in 4h
- TodayUSDCore CPI m/m●●●Forecast 0.2%Previous 0.3%in 4h
- TodayUSDCPI●●●Forecast 338.683Previous 336.298in 4h
- TodayUSDCPI m/m●●●Forecast 0.5%Previous 0.6%in 4h
- TodayUSDCore CPI n.s.a. m/m●●●Previous 0.4%in 4h
- November 12, 2026USDInitial Jobless Claims●●●in 2 days
All times UTC. Assessed against the consensus forecast, otherwise against the previous value.
Both worlds over time
Technical and news signals of the last 30 days on one timeline.
What is being reported about VNRX
Frequently asked questions about VolitionRx
What did VolitionRx change about its convertible note?
The company prepaid part of the note, cutting the outstanding principal to $0.7 million, and secured a moratorium on conversion rights until January 2027. In total, debt has fallen by more than $5.0 million since June 30, 2026, giving a more stable capital structure for ongoing operations.
When does VolitionRx report its third quarter results?
The earnings call is scheduled for Friday, November 13, 2026 at 8:30 a.m. ET. The announcement itself was only a scheduling notice without figures or guidance, so the results, not this notice, will be the potential price driver for VNRX.
What is the share price trigger on the convertible note?
The moratorium on conversion rights runs until January 2027, but it can be triggered earlier if the closing share price reaches or exceeds $0.275. The remaining $0.7 million of principal is still subject to future conversion or repayment, so the limit on dilution depends on the share price.
📝 Overview Generated automatically
VNRX has been the subject of 2 signals across 2 articles in the last 365 days. Sentiment skews Bullish (50%).
Breakdown: 1 bullish, 0 bearish, 1 neutral.
Most-cited catalysts: Prepayment of convertible note reducing principal to $0.7 million (1×), Total debt reduction of over $5.0 million since June 30, 2026 (1×). Most-cited risk factors: Conversion rights may be triggered earlier if the closing share price reaches or exceeds $0.275 (1×), Remaining $0.7 million principal balance still subject to future conversion or repayment (1×).